Prospects for combining immune checkpoint blockade with PARP inhibition

The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cance...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research